Omnicell (NASDAQ:OMCL) Stock Rating Upgraded by StockNews.com

Omnicell (NASDAQ:OMCL) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Wednesday.

A number of other analysts have also commented on the company. Bank of America boosted their price target on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and upped their price target for the stock from $26.00 to $39.00 in a research report on Friday, August 2nd. Benchmark reiterated a “buy” rating and issued a $38.00 price objective on shares of Omnicell in a report on Monday, July 15th. Wells Fargo & Company increased their target price on shares of Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Omnicell currently has an average rating of “Moderate Buy” and an average price target of $37.83.

Omnicell Trading Down 0.6 %

NASDAQ OMCL opened at $42.83 on Wednesday. Omnicell has a one year low of $25.12 and a one year high of $56.06. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22. The firm has a market cap of $1.97 billion, a P/E ratio of -93.11, a P/E/G ratio of 50.19 and a beta of 0.83. The stock’s 50-day moving average is $37.09 and its 200-day moving average is $31.52.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. During the same quarter in the previous year, the firm posted $0.29 earnings per share. The business’s revenue was down 7.4% on a year-over-year basis. Sell-side analysts anticipate that Omnicell will post 0.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omnicell

Hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its holdings in Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after purchasing an additional 1,000 shares during the last quarter. EntryPoint Capital LLC raised its holdings in Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares during the period. CWM LLC lifted its position in Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares during the last quarter. Benjamin Edwards Inc. boosted its holdings in shares of Omnicell by 36.4% during the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after acquiring an additional 868 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of Omnicell in the second quarter valued at approximately $104,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.